+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are evaluating the effectiveness and quality of life outcomes of neoadjuvant endocrine therapy compared to chemotherapy in participants with early or locally advanced hormone receptor-positive, HER2-negative breast cancer who have no detectable circulating tumor DNA ctDNA in their blood. This study focuses on determining if endocrine therapy is at least equivalent to chemotherapy for those who respond to initial aromatase inhibitor treatment, using the modified preoperative endocrine prognostic index PEPI score as the main measure. Participants initially provide blood and tumor samples for ctDNA testing using the SignateraTM test. They then take aromatase inhibitor therapy for 4 weeks during a Run-in Phase, with a tumor biopsy after 3 weeks to assess Ki-67 levels. Based on ctDNA results and Ki-67 values, participants are assigned to one of three groups neoadjuvant aromatase inhibitor or tamoxifen treatment, neoadjuvant chemotherapy for endocrine responders, or chemotherapy for non-responders. Treatment lasts 6 to 8 months depending on the group. During the study, participants visit the clinic several times, including before starting treatment, after 3 weeks of endocrine therapy, before beginning the main treatment, mid-therapy, after treatment completion, for surgery and post-surgery checkups, and annually for 5 years after surgery. They provide blood samples for ongoing ctDNA assessment and complete questionnaires on quality of life, symptoms, and sexual health. The study tracks outcomes like PEPI score at surgery and long-term survival and disease-free survival over 5 years.

Age: 18Years - 100YearsAll GendersPhase Not Applicable
14 locations
E

Actively Recruiting

Researchers are evaluating the use of percutaneous auricular Vagus Nerve Stimulation pVNS combined with standard rehabilitation training in patients with chronic musculoskeletal or myofascial back pain. This pilot study aims to assess the feasibility, efficacy, and safety of personalized pVNS therapy using the VIVO4 wearable medical device, compared to standard care alone, during a 3-week inpatient rehabilitation period. The study builds on previous findings that pairing vagus nerve stimulation with exercise can benefit pain management in stroke and back pain patients. Participants will be randomly assigned to one of two groups the treatment group will receive personalized pVNS therapy alongside standard rehabilitation care, while the control group will receive standard care only. Personalized pVNS involves adjusting the stimulation amplitude to a comfortable tingling sensation at the ear to activate certain nerve fibers without causing pain. Participants and investigators can adjust the stimulation levels using the VIVO4 device during the rehabilitation stay. Treatment lasts for 3 weeks, with optional follow-up periods at 3 and 6 months to evaluate sustained effects. During the study, participants will undergo assessments including questionnaires on pain, disability, usability of the device, quality of life, and mental health. Researchers will monitor pain levels, functional outcomes using the Oswestry Disability Index, and socioeconomic data from baseline through treatment and follow-up. All medications and therapies used by participants will be carefully recorded. The total participation period includes the 3-week treatment and follow-up evaluations to assess lasting benefits and safety.

Age: 30Years - 65YearsAll GendersPhase Not Applicable
1 location